IMA Kerala Medical Journal

  • Home
  • AI Submit
  • Current Issue
  • Guidelines
  • Editorial Board
  • Archives
  • Contact

Opioid Dependence: Neuro-Biology, Clinical Features, Diagnosis and Management

Review Article, Volume 10 Issue 3 – July to September 2017

Authors

Sharon Thomasa, Nagamony PSb, Sheena Varughesea, Roy Abraham Kallivayalila
a. Department of Psychiatry, Pushpagiri Institute of Medical Sciences & Research Centre, Thiruvalla, Kerala;
b. Department of Philosophy, NSS Hindu College, Changanacherry, Kerala


Abstract

Opioids have been in use since centuries, but there is a growing concern regarding its illicit use among the youth, especially in India. Activation of mesolimbic reward pathway and dysfunction of the frontal inhibitory mechanisms contribute to the additive nature of opioids. The main goal of the management is detoxification, relapse prevention and adaptive and social rehabilitation. Management comprises of pharmacological and non pharmacological methods. Among the pharmacological methods, opioid substitution treatment (OST) has garnered wide recognition, with Buprenorphine being the most widely used agent. Methadone, naltrexone, clonidine and slow release oral morphine are other agents.
Keywords: Opioid dependence, Neuro-biology, Opioid- related disorders, Clinical features, Management, OST, Harm reduction, Newer approaches, Ethics


Full Article

Download Full Article (PDF)

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

Recent Articles

  • Challenging Cholesterol
  • Problems in the Implementation of Biomedical Waste Management Programme at Government Medical College Hospital, Thiruvananthapuram – A Qualitative Study
  • Do We Achieve target Lipid Levels with Statins in Patients with Coronary Artery Disease?
  • Clinico-Pathology Study of Vitellointestinal Remnants in Children
  • Understanding Depressive Disorders
  • Interstitial Pneumonia in Chikungunya Infection
  • Re-expansion Pulmonary Oedema
  • Mobile Phones and Health Hazards
  • Sitagliptin: The First in a New Class of DPP-4 Inhibitors for the Treatment of Type 2 Diabetes
  • Smoking Cessation: Initial Insights into a New Drug

Kerala Medical Journal All Rights Reserved | Powered by New Clinician